• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

移植相关性血栓性微血管病:移植物抗宿主病对治疗性血浆置换疗效的影响。

Transplantation-associated thrombotic microangiopathy: effect of concomitant GVHD on efficacy of therapeutic plasma exchange.

机构信息

Department of Haematology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.

出版信息

Bone Marrow Transplant. 2010 Apr;45(4):699-704. doi: 10.1038/bmt.2009.233. Epub 2009 Sep 21.

DOI:10.1038/bmt.2009.233
PMID:19767787
Abstract

Factors predictive of response to plasma exchange (PE) in treatment of transplantation-associated thrombotic microangiopathy (TA-TMA) are generally poorly understood. To determine any clinical or laboratory factors predictive of response to PE in treatment of TA-TMA, we retrospectively reviewed all 11 cases of TA-TMA treated with PE at out institution between December 2001 and March 2008. Response to PE was correlated with associated clinical conditions, grade of TA-TMA, TA-TMA index and lactate dehydrogenase (LDH) level at diagnosis. Overall response to PE was 27%, with three complete responses (CRs) and eight non-responses (NRs) seen. Response to PE was significantly associated with the absence of acute GVHD at TA-TMA diagnosis, with three CR in four patients without active acute GVHD, and NR in seven patients with acute GVHD (P=0.024). There was no significant association seen between response to PE grade of TA-TMA (P=0.179), TA-TMA index (P=0.25) or LDH measurements (P=0.31). Our experience in use of therapeutic PE for management of TA-TMA suggests that PE may indeed be effective in the treatment of this disorder, depending on the clinical circumstance in which it develops. PE is potentially efficacious in the absence of active acute GVHD, and ineffective when acute GVHD is manifest.

摘要

预测血浆置换(PE)治疗移植相关血栓性微血管病(TA-TMA)反应的因素通常理解不佳。为了确定治疗 TA-TMA 时预测 PE 反应的任何临床或实验室因素,我们回顾性分析了 2001 年 12 月至 2008 年 3 月期间在我院接受 PE 治疗的 11 例 TA-TMA 患者。PE 反应与相关临床情况、TA-TMA 分级、TA-TMA 指数和乳酸脱氢酶(LDH)水平相关。PE 总体反应率为 27%,其中 3 例完全缓解(CR)和 8 例无反应(NR)。PE 反应与 TA-TMA 诊断时无急性 GVHD 显著相关,4 例无急性 GVHD 的患者中有 3 例 CR,7 例有急性 GVHD 的患者中有 8 例 NR(P=0.024)。PE 反应与 TA-TMA 分级(P=0.179)、TA-TMA 指数(P=0.25)或 LDH 测量值(P=0.31)之间无显著相关性。我们在使用治疗性 PE 治疗 TA-TMA 方面的经验表明,PE 可能确实对这种疾病有效,具体取决于其发生的临床情况。在无急性 GVHD 时,PE 可能有效,而在急性 GVHD 时无效。

相似文献

1
Transplantation-associated thrombotic microangiopathy: effect of concomitant GVHD on efficacy of therapeutic plasma exchange.移植相关性血栓性微血管病:移植物抗宿主病对治疗性血浆置换疗效的影响。
Bone Marrow Transplant. 2010 Apr;45(4):699-704. doi: 10.1038/bmt.2009.233. Epub 2009 Sep 21.
2
Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning.异基因造血细胞移植后高剂量与非清髓性预处理后血栓性微血管病的比较。
Bone Marrow Transplant. 2010 Apr;45(4):689-93. doi: 10.1038/bmt.2009.230. Epub 2009 Aug 31.
3
Outcomes of plasma exchange in patients with transplant-associated thrombotic microangiopathy based on time of presentation since transplant.基于移植后发病时间的移植相关血栓性微血管病患者血浆置换的结局
J Clin Apher. 2015 Jun;30(3):147-53. doi: 10.1002/jca.21352. Epub 2014 Sep 17.
4
[Allogeneic hematopoietic stem cell transplantation associated thrombotic microangiopathy: 16 cases report and literature review].[异基因造血干细胞移植相关血栓性微血管病:16例报告及文献复习]
Zhonghua Xue Ye Xue Za Zhi. 2016 Aug 14;37(8):666-70. doi: 10.3760/cma.j.issn.0253-2727.2016.08.007.
5
Early clinical indicators of transplant-associated thrombotic microangiopathy in pediatric neuroblastoma patients undergoing auto-SCT.儿童神经母细胞瘤患者自体外周血造血干细胞移植后移植相关血栓性微血管病的早期临床指标。
Bone Marrow Transplant. 2011 May;46(5):682-9. doi: 10.1038/bmt.2010.182. Epub 2010 Aug 9.
6
Transplant-associated microangiopathy in patients receiving tacrolimus following allogeneic stem cell transplantation: risk factors and response to treatment.异基因干细胞移植后接受他克莫司治疗的患者的移植相关微血管病:危险因素及治疗反应
Biol Blood Marrow Transplant. 2007 Apr;13(4):469-77. doi: 10.1016/j.bbmt.2006.11.020. Epub 2007 Feb 8.
7
Clinical impact of thrombotic microangiopathy on the outcome of patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.血栓性微血管病对异基因造血干细胞移植后急性移植物抗宿主病患者预后的临床影响。
Bone Marrow Transplant. 2008 May;41(9):813-20. doi: 10.1038/sj.bmt.1705976. Epub 2008 Jan 21.
8
[Clinical analysis of 9 patients with transplant-related thrombotic microangiopathy].9例移植相关血栓性微血管病的临床分析
Zhonghua Nei Ke Za Zhi. 2019 Jun 1;58(6):423-427. doi: 10.3760/cma.j.issn.0578-1426.2019.06.005.
9
Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation.异基因造血干细胞移植后血栓性微血管病的最新共识标准的验证。
Transplantation. 2010 Oct 27;90(8):918-26. doi: 10.1097/TP.0b013e3181f24e8d.
10
Renal thrombotic microangiopathy associated with chronic humoral graft versus host disease after hematopoietic stem cell transplantation.肾血栓性微血管病与造血干细胞移植后慢性体液移植物抗宿主病相关。
Pathol Int. 2011 Jan;61(1):34-41. doi: 10.1111/j.1440-1827.2010.02608.x. Epub 2010 Nov 5.

引用本文的文献

1
Survival analysis of transplant-associated thrombotic microangiopathy under different diagnostic criteria and the efficacy of plasma exchange.不同诊断标准下移植相关性血栓性微血管病的生存分析及血浆置换的疗效。
Ann Transplant. 2023 Jun 20;28:e939890. doi: 10.12659/AOT.939890.
2
Treatment outcome and efficacy of therapeutic plasma exchange for transplant-associated thrombotic microangiopathy in a large real-world cohort study.在一项大型真实世界队列研究中,治疗性血浆置换治疗移植相关血栓性微血管病的治疗结果和疗效。
Bone Marrow Transplant. 2022 Apr;57(4):554-561. doi: 10.1038/s41409-022-01581-1. Epub 2022 Jan 25.
3
[Advances in the diagnosis and management of transplant-associated thrombotic microangiopathy].
[移植相关血栓性微血管病的诊断与管理进展]
Zhonghua Xue Ye Xue Za Zhi. 2021 Aug 14;42(8):693-699. doi: 10.3760/cma.j.issn.0253-2727.2021.08.018.
4
[Chinese consensus on the diagnosis and management of transplant-associated thrombotic microangiopathy (2021)].《移植相关血栓性微血管病诊断和管理中国专家共识(2021年版)》
Zhonghua Xue Ye Xue Za Zhi. 2021 Mar 14;42(3):177-184. doi: 10.3760/cma.j.issn.0253-2727.2021.03.001.
5
Variable clinical manifestations of hematopoietic stem cell transplant-associated thrombotic microangiopathy.造血干细胞移植相关血栓性微血管病的临床症状多样。
Pediatr Investig. 2019 Jan 8;2(4):253-256. doi: 10.1002/ped4.12100. eCollection 2018 Dec.
6
[How I treat transplant-associated thrombotic microangiopathy].[我如何治疗移植相关血栓性微血管病]
Zhonghua Xue Ye Xue Za Zhi. 2020 Apr 14;41(4):272-275. doi: 10.3760/cma.j.issn.0253-2727.2020.04.002.
7
Acute kidney injury in the patient with cancer.癌症患者的急性肾损伤
Kidney Res Clin Pract. 2019 Sep 30;38(3):295-308. doi: 10.23876/j.krcp.19.042.
8
Thrombotic microangiopathy following haematopoietic stem cell transplant.造血干细胞移植后的血栓性微血管病。
Pediatr Nephrol. 2018 Sep;33(9):1489-1500. doi: 10.1007/s00467-017-3803-4. Epub 2017 Oct 9.
9
Hematopoietic stem cell transplant-associated thrombotic microangiopathy: current paradigm and novel therapies.造血干细胞移植相关性血栓性微血管病:现有模式与新型疗法。
Bone Marrow Transplant. 2018 Feb;53(2):129-137. doi: 10.1038/bmt.2017.207. Epub 2017 Oct 2.
10
[Allogeneic hematopoietic stem cell transplantation associated thrombotic microangiopathy: 16 cases report and literature review].[异基因造血干细胞移植相关血栓性微血管病:16例报告及文献复习]
Zhonghua Xue Ye Xue Za Zhi. 2016 Aug 14;37(8):666-70. doi: 10.3760/cma.j.issn.0253-2727.2016.08.007.